Key Highlights

  • Seres sold VOWST to Nestlé Health Science in September 2024 and used proceeds to retire its entire $110 million Oaktree term loan; in June 2026 Nestlé agreed to pay $25 million more to buy out future VOWST milestones.
  • A July 8, 2026 trial readout showed 80% of SER-155 recipients achieved an immunosuppressive-free clinical response by Day 15 in immune checkpoint inhibitor-related enterocolitis (irEC), though durability faded by Day 43.
  • Seres cut its workforce roughly 30% in February 2026 and restructured a Cambridge lease in June 2026, extending projected cash runway from Q3 2026 to well into Q1 2027.
  • Its March 2026 10-K and May 2026 10-Q both disclose substantial doubt about the company's ability to continue as a going concern absent new financing.

Seres (NASDAQ:MCRB) Therapeutics has spent two years shedding assets, staff and debt while betting its remaining cash on early-stage microbiome programs. New SER-155 data in a cancer-related bowel complication, alongside cash-preserving deals with Nestlé Health Science, mark the latest turns in a company still working to prove it can fund what comes next.

A Small-Cap Biotech Rebuilding Around a Smaller Pipeline

Seres Therapeutics, Inc. (MCRB) spent 2025 and 2026 in continuous contraction, trading the scale of a commercial-stage company for that of an early clinical developer. The Cambridge, Massachusetts firm once developed VOWST, the first FDA-approved oral microbiome therapeutic, but sold that franchise to Nestlé Health Science in 2024. Since then, management has cut costs, changed leaders and refocused on inflammatory and immune diseases. A mid-2026 readout on lead candidate SER-155 in a serious side effect of cancer immunotherapy signals where remaining cash is directed. Whether that bet pays off before cash runs out is the central question for the stock.

From Commercial Ambitions to a Live-Biotherapeutics Research Shop

Seres built a discovery platform that identifies gut bacteria linked to disease states and designs cultivated bacterial consortia to correct those imbalances. That produced VOWST, approved to prevent recurrence of Clostridioides difficile infection, which Seres divested to a Nestlé Health Science affiliate in a transaction that closed September 30, 2024. Seres now calls itself a clinical-stage biotechnology company focused on live biotherapeutics for inflammatory and immune diseases, led by SER-155, initially developed for allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients and now also tested in irEC. Seres no longer generates product revenue; its income statement shows only grant revenue from a CARB-X award.

Seres Therapeutics (MCRB) Pins Its Near-Term Story on SER-155 Data

The catalyst most tied to MCRB stock in 2026 is a July 8, 2026 readout from an investigator-sponsored trial of SER-155 in irEC, run at Memorial Sloan Kettering Cancer Center. In the open-label study of 15 patients with moderate-to-severe irEC, 12, or 80%, achieved an "immunosuppressive-free clinical response" at Day 15, the primary endpoint, meaning improved diarrhea symptoms without corticosteroids; five reached complete symptom resolution. By Day 43, only five maintained response, with most others requiring non-systemic immunosuppressive treatment. Seres reported no drug-related serious adverse events. Management is "engaging with potential partners, including companies with ICI franchises," but has not announced a follow-on study. SER-155's allo-HSCT program, carrying FDA Breakthrough Therapy and Fast Track designations, is "Phase 2 ready," but the roughly 248-patient study remains paused pending funding.

A Quarter Defined by Lower Spending and a Swing to Loss

Seres reported a net loss of $19.9 million for the first quarter of 2026, versus net income of $32.7 million a year earlier, per its May 5, 2026 release. The prior-year income reflected a $50 million Nestlé installment payment and $6.3 million of transition-service reimbursements, neither repeated in 2026. R&D expense rose to $13.2 million from $11.8 million; G&A fell to $8.1 million from $11.9 million; manufacturing-services expense dropped to zero as Nestlé transition work concluded at 2025 year-end. For full-year 2025, Seres reported net income from continuing operations of $5.7 million versus a $125.8 million loss in 2024, aided by an $80.7 million gain on the VOWST sale and lower R&D and G&A of $49.1 million and $39.2 million.

Cash, Debt and the Going-Concern Question

Seres ended the first quarter of 2026 with $29.8 million in cash, down from $45.8 million at year-end 2025. Its balance sheet carries no term debt: the $250 million Oaktree Fund Administration credit facility, with $110 million outstanding as of June 30, 2024, was fully repaid and terminated at the September 2024 VOWST closing, when Seres paid Oaktree roughly $128 million in principal, interest, a yield-protection premium and an exit fee. On June 5, 2026, Seres said Nestlé will pay $25 million in two installments, July and October 2026, to buy out future VOWST milestones, alongside a restructured Cambridge lease cutting space and rent, extending runway from Q3 2026 to "well into the first quarter of 2027." Its March 2026 10-K and May 2026 10-Q both disclose substantial doubt about the company's ability to continue as a going concern absent financing that cannot be assumed probable under accounting rules.

Seres also carries Nasdaq listing history: after a 2024 bid-price deficiency notice, it executed a 1-for-20 reverse split effective April 21, 2025.

Where Growth Could Come From, and When

Seres' near-term opportunities center on three efforts. The irEC data give it a case to make to oncology-focused partners, given a checkpoint-inhibitor market the company describes as worth more than $50 billion in 2025 and irEC affecting an estimated one in four U.S. ICI recipients. SER-603, still in IND-enabling studies for inflammatory bowel disease, drew a "Poster of Distinction" at Digestive Disease Week in May 2026. SER-428, a liquid SER-155 formulation for ICU patients, is advancing toward a Phase 1b trial with Columbia University under CARB-X funding. None has secured capital for a registration-enabling trial, and the allo-HSCT Phase 2 study remains paused.

What Could Go Wrong for Seres Therapeutics Shareholders

Seres says it will need funding beyond the third quarter of 2026, and future financings or partnerships cannot be assumed to close on favorable terms. A roughly 30% workforce cut in February 2026 already trimmed capacity, and further reductions could constrain execution. The irEC data come from a small, open-label, uncontrolled study with no placebo arm, and the fade in response between Day 15 and Day 43 raises durability questions. The allo-HSCT program depends on outside funding not yet secured despite being "Phase 2 ready" for months. Leadership turnover, with Kender named Executive Chair and interim CEO in March 2026 as former co-CEOs DesRosier and Thorell shifted into legal and financial roles, adds uncertainty, as does the company's Nasdaq compliance history.

Outlook

The optimistic case rests on real, if early, proof of concept: SER-155's allo-HSCT data showed a statistically significant 77% relative reduction in bloodstream infections, and the newer irEC data extend that mechanism into a large, underserved niche that could attract a partner. The base case is a capital-constrained research organization extending runway through asset monetization and cost cuts while seeking a partner for SER-155's next study. The downside case is that no partnership materializes before cash is exhausted, forcing restructuring, dilutive financing, or the wind-down scenarios the company lists as risks.

Conclusion

Seres Therapeutics, Inc. (MCRB) has dismantled the larger company it once was, retiring its Oaktree debt, divesting VOWST, cutting staff and shrinking its leased footprint to fund a narrower set of live-biotherapeutic programs. The July 2026 SER-155 irEC data give it a fresh, if early, story for prospective partners, but going-concern language in its filings makes clear Seres' next chapter depends on financing it has not yet secured.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.